- 期刊
Crizotinib Treatment Failure in a Patient with Positive ALK-Rearranged Advanced-Stage Squamous Cell Lung Cancer - Case Report and Literature Review
Crizotinib對於一位間變性淋巴瘤激酶重組的晚期鱗狀上皮肺癌病人的治療失敗－案例報告及文獻回顧
摘要
In the era of target therapy, tyrosine kinase inhibitors are mainstream therapy for advanced-stage lung cancer with driver mutations present. Crizotinib has been documented to have a high overall response rate and good efficacy in the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer, as either first-line or rescue treatment. However, ALK rearrangement is rarely seen in lung squamous cell cancer. The overall response rate for crizotinib is uncertain, though some published case reports showed a positive response. Here, we present a case of positive ALK-rearranged advanced lung squamous cell cancer with a failed response to crizotinib treatment.
並列摘要
在標靶治療的時代中，酪胺酸激酶抑制劑是有驅動突變的晚期肺癌的治療主流。而Crizotinib已被證實對於有間變性淋巴瘤激酶重組的非小細胞肺癌病人在第一線或是後線的治療中，有一定程度的反應率和效果。可是，在鱗狀上皮細胞癌有間變性淋巴瘤激酶重組的比率非常低，雖然有少數病例報告顯示crizitinib對於此族群的病人有治療反應，但整體的反應率還無法確定。在此，我們提出一個個案報告，一位有間變性淋巴瘤激酶重組的晚期鱗狀上皮細胞肺癌的病人，在使用crizotinib治療後沒有反應且疾病迅速惡化。